



**PATENT**/Docket No. PC9960D  
Serial No. 10/771861  
Page 1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1624  
 Examiner : Sudhaker B. Patel  
 Applicant(s) : Kazuo Ando et al.  
 Serial Number : 10/771,861  
 Filed : February 3, 2004  
 For : Sulfonylbenzene Compounds as Anti-Inflammatory/Analgesic Agents

Commissioner of Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

**TERMINAL DISCLAIMER**

I, Karen DeBenedictis, am the attorney of record for the above identified patent application as evidenced by the Power of Attorney filed in the present application on February 3, 2004. I am making this petition on behalf of Pfizer Inc, the assignee of 100 percent of the present invention. As the attorney of record, I am empowered to act on behalf of the assignee and, in accordance with 37 C.F.R. 1.321(b)(i)(iv), to sign this terminal disclaimer.

**Certificate Under 37 C.F.R. § 3.73(b)**

Your petitioner, Pfizer Inc, certifies that they are the owner of the entire right, title and interest in and to the above identified patent application (Serial No. 10/771861) and to US Patent Nos. 6,727,238; 6,608,095; and 6,294,558. Your petitioner owns the entire right, title, and interest of these patents and this application by nature of the assignments executed and filed for all of these patents and this application. The assignments for the above identified patents and this application were recorded on June 26, 2000 on Reel 010940, Frame 0184, and Reel 010940, Frame 0156 with the United States Patent and Trademark Office. The above identified patent application (Serial No. 10/771861) is a continuation of Patent No. 6,727,238, which is a division of 6,608,095 which is a division of Patent No. 6,294,558.

**Terminal Disclaimer**

The owner, Pfizer Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term prior patent nos. 6,727,238; 6,608,095; and 6,294,558 as the term of said prior patents are defined in 35 U.S.C 154 and 173, and as  
 03/30/2005 LWONDIM2 00000106 210718 10771861

01 FC:1814

130.00 DA

FORM PTORSP  
Rev. 5/1/03

**PATENT**/Docket No. PC9960D  
Serial No. 10/771861  
Page 2


the term of said prior patents is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patents are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

Limitation on the Disclaimer

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patents, "as the term of said prior patents is presently shortened by any terminal disclaimer," in the event that said prior patents later:

expire for failure to pay a maintenance fee;  
is held unenforceable;  
is found invalid by a court of competent jurisdiction;  
is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321;  
has all claims cancelled by a reexamination certificate;  
is reissued; or  
is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Respectfully submitted,

  
Karen DeBenedictis, Attorney of Record

Registration No. 32,977

Date: 3/16/05

Pfizer Inc.  
Patent Department  
2800 Plymouth Road  
Ann Arbor, MI 48105

Telephone No. (734) 622-3374

FORM PTORSP  
Rev. 5/1/03